Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Aprea Therapeutics, a US-based cancer drug spinout of Karolinska Institute, has raised $85m yesterday in an initial public offering on the Nasdaq Global Select Market.
The company issued approximately 5.7 million shares on Tuesday priced at $15 each, in the middle of the IPO’s $14 to $16 range. Its shares rose by more than a third to close at $20.50 on its first day of trading yesterday, giving it a market cap of about $408m.
Founded in…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
